terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 12, 2026

Is It Really Safe to Invest in AI Stocks and ETFs Right Now? Here's What the Experts Say.

View original at nasdaq.com
Is It Really Safe to Invest in AI Stocks and ETFs Right Now? Here's What the Experts Say. Key Points AI stocks have come under recent pressure amid concerns about spending…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI data center capex is expected to grow by another 40% to 50% next year, bringing it to around $1.5 trillion

    60% confidence
  • Computing demand is so strong that the economics of providing this computing power to third parties can be more attractive than for internal projects

    60% confidence
  • Raised 2026 capex guidance to $52-56 billion after extensive diligence talking to his own customers and his customers' clients, expressing confidence in continued AI chip demand

    60% confidence
  • This capex growth is supported by a combination of AI agent adoption, token growth, and current market supply constraints

    60% confidence
  • According to a survey done before the start of the year, 90% of investors polled planned to hold or buy more AI stocks this year, and only 7% planned to decrease their exposure

    60% confidence
  • Recommends the Vanguard S&P 500 ETF as a core holding investors can consistently dollar-cost average into, alongside AI leaders Nvidia, Alphabet, Meta Platforms, AMD, Broadcom, and TSMC for long-term holding

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Is It Really Safe to Invest in AI Stocks and ETFs Right Now? Here's What the Experts Say. — Source | Via News | pt.VIA.NEWS